PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
1Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China. jimei90@sina.com.
Abstract:
Immunotherapy has become a crucial modality for non-small-cell lung cancer treatment. Recently, two immune checkpoints, PD-1 and PD-L1, have emerged as important targets for immunotherapy. Their antitumor efficacy has been confirmed by in vitro and in vivo studies. But the correlation between PD-1/PD-L1 expression and EGFR expression was controversial and needs more evidences to support the combination of PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors.
Insights
Immunotherapy targeting PD-1/PD-L1 shows promise for non-small-cell lung cancer. Further research is needed to confirm the link between PD-1/PD-L1 and EGFR expression for combination therapies.
Area of Science:
- Oncology
- Immunology
- Medical Research
Background:
- Immunotherapy is a key treatment for non-small-cell lung cancer (NSCLC).
- Immune checkpoints programmed cell death protein 1 (PD-1) and its ligand (PD-L1) are significant immunotherapy targets.
- Preclinical studies confirm the antitumor effects of targeting PD-1/PD-L1.
Purpose of the Study:
- To investigate the correlation between PD-1/PD-L1 expression and epidermal growth factor receptor (EGFR) expression in NSCLC.
- To evaluate the potential for combining PD-1/PD-L1 inhibitors with tyrosine kinase inhibitors (TKIs).
Main Methods:
- Review of existing in vitro and in vivo studies on PD-1/PD-L1 and EGFR.
- Analysis of controversial findings regarding the correlation between PD-1/PD-L1 and EGFR expression.
Main Results:
- The relationship between PD-1/PD-L1 expression and EGFR expression in NSCLC remains controversial.
- Current evidence is insufficient to definitively support the combined use of PD-1/PD-L1 inhibitors and TKIs.
Conclusions:
- More robust evidence is required to establish the correlation between PD-1/PD-L1 and EGFR.
- Further research is essential to guide the optimal combination strategies for NSCLC treatment involving immunotherapy and targeted therapy.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:38Mitogens and the Cell Cycle